Innovative Diagnostic Platform Diaceutics offers DXRX, the world's first diagnostic commercialization platform for precision medicine, providing a unique value proposition for pharmaceutical companies seeking to optimize diagnostic test launches and patient access.

Strategic Industry Partnerships Recent collaborations with Partner Therapeutics and Cornerstone AI highlight Diaceutics' active engagement in expanding its service offerings and enhancing laboratory data quality, creating cross-selling opportunities in precision oncology and data analytics.

US Market Expansion With recent office expansions and new data partnership agreements in the United States, there is significant opportunity to promote Diaceutics' solutions to major US pharma and biotech companies focused on precision diagnostics and personalized medicine.

New Service Launches The introduction of the Pathology Engagement Liaisons service and ongoing contract wins demonstrate Diaceutics' focus on innovative service offerings, indicating potential for upselling enhanced diagnostic engagement solutions.

Financial Growth & Recognition Generating between 50 and 100 million USD in revenue with ongoing investments and being recognized as a top workplace, Diaceutics presents a compelling partner for pharmaceutical companies prioritizing cutting-edge diagnostics and strategic collaborations.